Company: PSTV
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0000950170-25-047698
Chunk: 9

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 16
Chunk 9
---
, Inc., CNSide Diagnostics, LLC and Iroqouis Master Fund Ltd., as collateral agent for the purchasers names therein 
     
    8-K
    001-34375Exhibit 10.4
    02/18/2025

    10.31
    Subsidiary Guarantee, dated as of February 13, 2025, by and among CNSide Diagnostics, LLC and the purchasers named therein 
     
    8-K
    001-34375Exhibit 10.5
    02/18/2025

    10.32
    Registration Rights Agreement, dated February 13, 2025, by and among Plus Therapeutics, Inc. and the purchasers named therein
     
    8-K
    001-34375Exhibit 10.6
    02/18/2025

    10.33
    Second Amendment to Securities Purchase Agreement, dated May 5, 2024, as amended on May 9, 2024, by and among Plus Therapeutics, Inc. and the purchasers named therein
     
    8-K
    001-34375Exhibit 10.7
    02/18/2025

    10.34
    Securities Purchase Agreement, dated as of March 4, 2025
     
    8-K
    001-34375Exhibit 10.1
    03/04/2025

    10.35
    Registration Rights Agreement, dated as of March 4, 2025
     
    8-K
    001-34375Exhibit 10.2
    03/04/2025

    10.36
    First Amendment to Securities Purchase and Exchange Agreement, dated as of March 4, 2025
     
    8-K
    001-34375Exhibit 10.3
    03/04/2025

    19
    Insider Trading Policy
    X

    21
    List of Subsidiaries
    X

    23.1
    Consent of BDO USA, P.C., Independent Registered Public Accounting Firm
    X

    31.1
    Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rule 13a-14(a), as adopted pursuant to Section 302 of the Sar